To determine whether IL-21 also sensitizes LPSCs to cell-based therapies currently used in hematological malignancies, we treated LPSCs from two newly diagnosed patients with AML with CAR T cells targeting the AML surface antigen CD70 in the presence and absence of rh-IL-21. The gene discussed is IL21; the disease is hematologic disorder.